Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
January 12, 2021
Date of Patent:
May 25, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
December 18, 2020
Date of Patent:
May 18, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: Methods of expanding tumor infiltrating lymphocytes (TILs) in the presence of an adenosine A2A receptor (A2aR) antagonist, such as vipadenant, CPI-444 (ciforadenant), SCH58261, SYN115, ZM241385, SCH420814, a xanthine superfamily A2aR antagonist, or related adenosine receptor 2A antagonist, and uses of expanded TILs in the treatment of diseases such as cancer are disclosed herein. In addition, therapeutic combinations of TILs and A2aR antagonists, including compositions and uses thereof in the treatment of diseases such as cancer are disclosed herein.
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. The methods may comprise gene-editing at least a portion of the TILs to enhance their therapeutic efficacy. Such TILs find use in therapeutic treatment regimens.
Abstract: In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.
Type:
Application
Filed:
January 5, 2021
Publication date:
April 29, 2021
Applicant:
Iovance Biotherapeutics, Inc.
Inventors:
Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
April 14, 2020
Date of Patent:
March 23, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
April 14, 2020
Date of Patent:
March 23, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
April 14, 2020
Date of Patent:
March 16, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
April 14, 2020
Date of Patent:
March 16, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
April 14, 2020
Date of Patent:
March 2, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
January 5, 2018
Date of Patent:
January 19, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
May 29, 2019
Date of Patent:
June 30, 2020
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
January 17, 2020
Date of Patent:
May 19, 2020
Assignee:
IOVANCE, BIOTHERAPEUTICS, INC.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
May 29, 2019
Date of Patent:
May 12, 2020
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
May 29, 2019
Date of Patent:
May 5, 2020
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
November 15, 2018
Date of Patent:
January 21, 2020
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
November 28, 2018
Date of Patent:
November 5, 2019
Assignee:
IOVANCE BIOTHERAPEUTICS, INC.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
September 19, 2018
Date of Patent:
September 24, 2019
Assignee:
IOVANCE BIOTHERAPEUTICS, INC.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze